AbbVie wins FDA approval for oral treatment for endometriosis pain

AbbVie Inc. shares (abbv) rose 1.4% in premarket trade Tuesday, after the company said the U.S. Food and Drug Administration has approved its Orilissa oral gonadotropin-releasing hormone antagonist as a treatment for endometriosis pain.